US20070198080A1 - Coatings including an antioxidant - Google Patents
Coatings including an antioxidant Download PDFInfo
- Publication number
- US20070198080A1 US20070198080A1 US11/528,891 US52889106A US2007198080A1 US 20070198080 A1 US20070198080 A1 US 20070198080A1 US 52889106 A US52889106 A US 52889106A US 2007198080 A1 US2007198080 A1 US 2007198080A1
- Authority
- US
- United States
- Prior art keywords
- medical device
- rapamycin
- sodm
- coating
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1303—Paper containing [e.g., paperboard, cardboard, fiberboard, etc.]
- Y10T428/1307—Bag or tubular film [e.g., pouch, flexible food casing, envelope, etc.]
Definitions
- This invention generally relates to a method of providing an antioxidant to a coating on a medical device such as a drug-delivery stent.
- Blood vessel occlusions are commonly treated by mechanically enhancing blood flow in the affected vessels, such as by employing a stent.
- Stents are used not only for mechanical intervention but also as vehicles for providing biological therapy.
- the stent can be coated with a biocompatible polymeric coating.
- the biocompatible polymeric coating can function either as a permeable layer or a carrier to allow a controlled delivery of the agent.
- stents work well mechanically, the chronic issues of restenosis and, to a lesser extent, stent thrombosis remain.
- Pharmacological therapy in the form of a drug delivery stent appears to be a feasible means to tackle these issues.
- Subacute thrombosis and neointimal hyperplasia are considered to be the leading complications after stenting.
- Various factors are believed to be involved in the process.
- Methods for reducing thrombosis and restenosis have been previously proposed. However, those methods are less satisfactory for reducing thrombosis or restenosis associated with stenting.
- a coating that includes an antioxidant for a medical device.
- the coating includes a polymer matrix, an antioxidant, and optionally heparin or a bioactive agent.
- the coating can include a biobeneficial material.
- the coating can be biodegradable or nondegradable.
- the medical device can be a stent.
- the stent itself, can be a polymeric biodegradable, bioerodable or bioabsorbable stent, terms which are used interchangeably unless specifically indicated, which can include the bioactive agent embedded in the body of the stent or coating in the stent.
- the antioxidant can be embedded within the coating of the body of the medical device. In some embodiments, the antioxidant can be attached to the surface of the coating or surface of the medical device.
- a coating or device can include two ore more antioxidants, at least one of the antioxidant can be butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), Vitamin E, a super-oxide dismutase mimetic (SODm), or combinations thereof.
- BHT butylated hydroxytoluene
- BHA butylated hydroxyanisole
- SODm super-oxide dismutase mimetic
- bioactive agent examples include, but are not limited to, paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometas
- the medical device having the features described herein can be used for treating, preventing, or ameliorating a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
- a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
- a coating that includes an antioxidant for a medical device.
- the coating includes a polymer matrix, an antioxidant, and optionally heparin or a bioactive agent.
- the coating can include a biobeneficial material.
- the coating can be biodegradable or nondegradable.
- the medical device can be a stent.
- the stent itself, can be a polymeric biodegradable, bioerodable or bioabsorbable stent, terms which are used interchangeably unless specifically indicated, which can include the bioactive agent embedded in the body of the stent or coating in the stent.
- the antioxidant can be embedded within the coating of the body of the medical device. In some embodiments, the antioxidant can be attached to the surface of the coating or surface of the medical device.
- a coating or device can include two ore more antioxidants, at least one of the antioxidant can be BHT, BHA, Vitamin E, a SODm, or combinations thereof.
- bioactive agent examples include, but are not limited to, paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometas
- the medical device having the features described herein can be used for treating, preventing, or ameliorating a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
- a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
- antioxidant refers to a substance that is capable of inhibiting, preventing, reducing or ameliorating oxidative reactions on another substance (e.g., a polymer, a bioactive agent or a therapeutic substance) when the antioxidant is used in a system (e.g., coating) that includes such other substances.
- another substance e.g., a polymer, a bioactive agent or a therapeutic substance
- oxygen scavenger is oxygen scavenger.
- the antioxidant useful in the present invention can be any volatile or non-volatile antioxidant, which can be natural or synthetic.
- Natural antioxidant refers to an antioxidant derived from a natural source, with or without modification.
- Synthetic antioxidant refers to any antioxidant that is not a natural antioxidant.
- ascorbic acid Vitamin C
- BHT, BHA, or a SODm can be a synthetic antioxidant.
- the antioxidant includes, but is not limited to, BHT, BHA, ascorbic acid (Vitamin C), folic acid, b vitamins, beta carotene, flavonoids, SODm, polyphenol antioxidants such as apigenin or combinations thereof.
- the term “antioxidant” can specifically exclude an antioxidant described above.
- the term “antioxidant” can specifically exclude BHT, BHA or a SODm.
- the term “antioxidant” can specifically exclude Vitamin E.
- the term “antioxidant” can specifically exclude a super-oxide dismutase mimetic (SODm).
- the antioxidant can specifically exclude one of folic acid, b vitamins, beta carotene, flavonoids, polyphenol antioxidants such as apigenin or combinations thereof.
- a coating or device can include a super-oxide dismutase (SOD) mimetic (SODm).
- SOD super-oxide dismutase
- the SODm can be attached to the surface of a coating or device.
- the SODm can be attached to the surface of a coating or device via covalent bonding or non-covalent bonding.
- Non-covalent bonding can be, e.g., ionic interaction, hydrogen bonding, or an interpenetrating network (IPN).
- SODm refers to any super-oxide dismutase (SOD) mimetic.
- SOD can have important effects on vascular pathophysiology.
- SOD1-deficient mice have been found to produce more superoxide than their wild-type controls and have decreased endothelium-dependent and -independent vasodilation.
- SOD1 overexpression in mice causes a decrease in VSMC proliferation in response to EGF but no change in the aortic hypertrophic response to Angiotensin II.
- a separate study with mice overexpressing SOD1 on the apoE ⁇ / ⁇ background showed no significant effect on aortic atherosclerotic lesion area.
- SOD2 deficiency is lethal in mice, and although partial SOD2 deficiency has been shown to cause an increase in atherosclerotic lesion formation at arterial branch points, there was no effect on vasomotor responses to serotonin, PGF2 ⁇ , or acetylcholine at baseline or after inhibition of SOD1 and SOD3 with diethyldithiocarbamate.
- SOD3 The second most abundant SOD isoform in blood vessels is SOD3, which is predominantly produced by VSMCs, but because of its location in the interstitium between ECs and VSMCs, it is thought to be essential for endothelial-dependent vasodilation by protecting NO as it diffuses from the ECs to the VSMCs.
- SODm examples include, but are not limited to, low molecular weight SOD synzymes having a Mn(II) coordinated in a macrocyclic pentamine ring (Ref: Riley D P, Weiss R H. JACS 1994; 116:387-388).
- a coating or device can specifically exclude a SODm described above.
- a SODm can be included in the coating or device or attached to the surface of a coating or device with or without a spacer. Attaching a SODm to the surface of a coating or device can be achieved by, for example, attaching the SODm to a polymer on the surface of the coating or the device via coupling of the reactive group in the SODm molecule to the polymer. In some embodiments, attaching a SODm to the polymer can be achieved by photo or thermally initiated radical coupling, which are well known in the art. In some embodiments, covalent attachment of a SODm to a polymer in the coating can be accomplished for example by reacting isocyanate group on the polymer chain with amino group on SODm (ref. Udipi, K, et al. J. biomaterial Mater. Res., 51, 549-560, 2000).
- attachment of a SODm to the polymer can be induced via photo activation.
- photo-reactive chemical(s) PRC
- PRC photo-reactive chemical
- a SODm can be bound to the PRC.
- a SODm can be covalently grafted to the carbon surface.
- photo-reactive chemicals are from the benzophenone family, i.e. benzophenone tetracarboxylic dianhydride, benzoylbenzoic acid, benzoyl benzoyl chloride, 4-benzoylbenzoic acid N-hydroxysuccinimide ester, benzoyl benzoyl amine, or from azide family, i.e. substituted phenyl azide and substituted acyl azide.
- the hydrogen extraction can be initiated by UV exposure of the PRC entity.
- the linking reaction between PRC to the SODm will be dependent on the specific structure of the molecule but can be readily carried out by an ordinary artisan.
- an amine functional group on SODm can react with an anhydride or acyl chloride of substituted benzophenone.
- the PRC can be coupled to the carbon surface first and then coupled with the SODm, or vice versa.
- a SODm can be attached to a polymer to form a SODm/polymer conjugate.
- the SODm/polymer conjugate can then be included in a formulation for forming a coating or a device.
- the SODm/polymer conjugate can have a covalent bond or non-covalent bond between the SODm and the polymer.
- antioxidants can be susceptible to oxidation or chemical changes under certain conditions.
- BHT and BHA at an elevated temperature can compromise the molecular integrity of the antioxidant or cause an volatile antioxidant to evaporate. Therefore, the conditions in the coating process or device forming process can affect the content of the antioxidant to minimize the reduction of the level of antioxidant.
- the loss of antioxidant(s) in the coating or device forming process can be reduced by controlling the processing conditions.
- control of processing conditions can be, e.g., duration of the process, exclusion of air or oxygen using inert atmosphere or lowering the processing temperature.
- the sterilization process can be conducted at a low temperature.
- a low temperature of sterilization refers to a temperature from about 25° C. to about 55° C., e.g., from about 30° C. to about 45° C.
- the baking process can be conducted at a low temperature or in vacuum.
- a low temperature of baking refers to a temperature from about 25° C. to about 55° C. with and without vacumm.
- the content of the antioxidant in a coating or device can be maintained or enhanced by adding an additional amount of the antioxidant (e.g., BHT or BHA) in the formulation forming the coating or device.
- additional amount depends from the chemical, physical or physiological nature of the antioxidant.
- the BHT level can be increased up to about 60 wt %.
- Other types of antioxidant such as vitamin C can have a level from about 60 wt %. If a coating already contains an active agent, the antioxidant can be added as a second active agent in the coating at an amount that can be up to about 50 wt %.
- the active agent can be, e.g., paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abcixima
- a coating or device having an antioxidant described herein can include one or more biocompatible polymer(s).
- the biocompatible polymer can be biodegradable (bioerodable or bioabsorbable) or nondegradable.
- Representative biocompatible polymers include, but are not limited to, poly(ester amide), polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(3-hydroxyheptanoate) and poly(3-hydroxyoctanoate), poly(4-hydroxyalkanaote) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanote), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate or 4-hydroxyalkanoate monomers described herein or blend
- PEO/PLA polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as HEMA, hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-P
- poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-glycolide), and poly(L-lactide-co-glycolide) can be used interchangeably with the terms poly(D,L-lactic acid), poly(L-lactic acid), poly(D,L-lactic acid-co-glycolic acid), or poly(L-lactic acid-co-glycolic acid), respectively.
- the coating or device can include a fluoropolymer such as a SolefTM polymer (e.g., PVDF-HFP).
- a fluoropolymer such as a SolefTM polymer (e.g., PVDF-HFP).
- the coating or device can further include a biobeneficial material.
- the biobeneficial material can be polymeric or non-polymeric.
- the biobeneficial material is preferably substantially non-toxic, non-antigenic and non-immunogenic.
- a biobeneficial material is one that enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non-thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent.
- biobeneficial materials include, but are not limited to, polyethers such as poly(ethylene glycol), copoly(ether-esters) (e.g. PEO/PLA), polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, poly(ethylene glycol) acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-tri
- PolyActiveTM refers to a block copolymer having flexible poly(ethylene glycol) and poly(butylene terephthalate) blocks (PEGT/PBT).
- PolyActiveTM is intended to include AB, ABA, BAB copolymers having such segments of PEG and PBT (e.g., poly(ethylene glycol)-block-poly(butyleneterephthalate)-block poly(ethylene glycol) (PEG-PBT-PEG).
- the biobeneficial material can be a polyether such as poly(ethylene glycol) (PEG) or polyalkylene oxide.
- polymers can be used as a drug carrier for active agents or topcoat to control the drug release.
- one active agent such as antioxidant
- another active agent anti-proliferative agent
- the coating or device having the features described herein can include one or more bioactive agents.
- the bioactive agents can be any bioactive agent that is therapeutic, prophylactic, or diagnostic. These agents can have anti-proliferative or anti-inflammatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, and antioxidant properties.
- agents can be cystostatic agents, agents that promote the healing of the endothelium such as NO releasing or generating agents, agents that attract endothelial progenitor cells, or agents that promote the attachment, migration and proliferation of endothelial cells (e.g., natriuretic peptide such as CNP, ANP or BNP peptide or an RGD or cRGD peptide), while quenching smooth muscle cell proliferation.
- suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities.
- Nucleic acid sequences include genes, antisense molecules that bind to complementary DNA to inhibit transcription, and ribozymes.
- Some other examples of other bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy.
- anti-proliferative agents include rapamycin and its functional or structural derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), and its functional or structural derivatives, paclitaxel and its functional and structural derivatives.
- rapamycin derivatives include methyl rapamycin (ABT-578), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.
- paclitaxel derivatives include docetaxel.
- antineoplastics or antimitotics examples include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.).
- antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ib/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax (Biogen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc.
- Angiomax Biogen, Inc., Cambridge, Mass.
- anti-inflammatory agents including steroidal and non-steroidal anti-inflammatory agents include tacrolimus, dexamethasone, clobetasol, combinations thereof.
- cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.).
- An example of an antiallergic agent is permirolast potassium.
- therapeutic substances or agents that may be appropriate include alpha-interferon, pimecrolimus, imatinib mesylate, midostaurin, bioactive RGD, and genetically engineered endothelial cells.
- the foregoing substances can also be used in the form of prodrugs or co-drugs thereof.
- the foregoing substances also include metabolites thereof or prodrugs of the metabolites.
- the foregoing substances are listed by way of example and are not meant to be limiting. Other active agents that are currently available or that may be developed in the future are equally applicable.
- the dosage or concentration of the bioactive agent required to produce a favorable therapeutic effect should be less than the level at which the bioactive agent produces toxic effects and greater than the level at which non-therapeutic results are obtained.
- the dosage or concentration of the bioactive agent can depend upon factors such as the particular circumstances of the patient, the nature of the trauma, the nature of the therapy desired, the time over which the ingredient administered resides at the vascular site, and if other active agents are employed, the nature and type of the substance or combination of substances.
- Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
- a medical device may be any suitable medical substrate that can be implanted in a human or veterinary patient.
- medical devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), heart valve prostheses, cerebrospinal fluid shunts, pacemaker electrodes, catheters, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, Calif.), anastomotic devices and connectors, orthopedic implants such as screws, spinal implants, and electro-stimulatory devices.
- the underlying structure of the device can be of virtually any design.
- the device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
- ELGILOY cobalt chromium alloy
- stainless steel 316L
- high nitrogen stainless steel e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
- BIODUR 108 cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol)
- tantalum nickel-t
- MP35N consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum.
- MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
- Devices made from bioabsorbable (e.g., bioabsorbable stent) or biostable polymers could also be used with the embodiments of the present invention.
- the medical device is a stent.
- the stent described herein is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways.
- a stent having the above-described coating is particularly useful for treating diseased regions of blood vessels caused by lipid deposition, monocyte or macrophage infiltration, or dysfunctional endothelium or a combination thereof, or occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis.
- Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, carotid and coronary arteries.
- an angiogram is first performed to determine the appropriate positioning for stent therapy.
- An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an artery or vein as an x-ray is taken.
- a guidewire is then advanced through the lesion or proposed site of treatment.
- Over the guidewire is passed a delivery catheter that allows a stent in its collapsed configuration to be inserted into the passageway.
- the delivery catheter is inserted either percutaneously or by surgery into the femoral artery, radial artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance.
- a stent having the above-described coating may then be expanded at the desired area of treatment.
- a post-insertion angiogram may also be utilized to confirm appropriate positioning.
Abstract
A coating including an antioxidant or a combination of antioxidant and another bioactive agent on a medical device is described.
Description
- This is a continuation-in-part application of U.S. application Ser. No. 11/189,216, filed on Jul. 25, 2005, the teachings of which are incorporated hereto by reference.
- 1. Field of the Invention
- This invention generally relates to a method of providing an antioxidant to a coating on a medical device such as a drug-delivery stent.
- 2. Description of the Background
- Blood vessel occlusions are commonly treated by mechanically enhancing blood flow in the affected vessels, such as by employing a stent. Stents are used not only for mechanical intervention but also as vehicles for providing biological therapy. To effect a controlled delivery of an active agent in stent medication, the stent can be coated with a biocompatible polymeric coating. The biocompatible polymeric coating can function either as a permeable layer or a carrier to allow a controlled delivery of the agent.
- Although stents work well mechanically, the chronic issues of restenosis and, to a lesser extent, stent thrombosis remain. Pharmacological therapy in the form of a drug delivery stent appears to be a feasible means to tackle these issues. Subacute thrombosis and neointimal hyperplasia are considered to be the leading complications after stenting. Various factors are believed to be involved in the process. Methods for reducing thrombosis and restenosis have been previously proposed. However, those methods are less satisfactory for reducing thrombosis or restenosis associated with stenting.
- The embodiments disclosed herein address the above described problems.
- Provided herein is a coating that includes an antioxidant for a medical device. The coating includes a polymer matrix, an antioxidant, and optionally heparin or a bioactive agent. In some embodiments, the coating can include a biobeneficial material. The coating can be biodegradable or nondegradable. In some embodiments, the medical device can be a stent. In some embodiments, the stent, itself, can be a polymeric biodegradable, bioerodable or bioabsorbable stent, terms which are used interchangeably unless specifically indicated, which can include the bioactive agent embedded in the body of the stent or coating in the stent.
- In some embodiments, the antioxidant can be embedded within the coating of the body of the medical device. In some embodiments, the antioxidant can be attached to the surface of the coating or surface of the medical device.
- In some embodiments, a coating or device can include two ore more antioxidants, at least one of the antioxidant can be butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), Vitamin E, a super-oxide dismutase mimetic (SODm), or combinations thereof.
- Some examples of the bioactive agent that can be included in the coating or medical device include, but are not limited to, paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
- The medical device having the features described herein can be used for treating, preventing, or ameliorating a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
- Provided herein is a coating that includes an antioxidant for a medical device. The coating includes a polymer matrix, an antioxidant, and optionally heparin or a bioactive agent. In some embodiments, the coating can include a biobeneficial material. The coating can be biodegradable or nondegradable. In some embodiments, the medical device can be a stent. In some embodiments, the stent, itself, can be a polymeric biodegradable, bioerodable or bioabsorbable stent, terms which are used interchangeably unless specifically indicated, which can include the bioactive agent embedded in the body of the stent or coating in the stent.
- In some embodiments, the antioxidant can be embedded within the coating of the body of the medical device. In some embodiments, the antioxidant can be attached to the surface of the coating or surface of the medical device.
- In some embodiments, a coating or device can include two ore more antioxidants, at least one of the antioxidant can be BHT, BHA, Vitamin E, a SODm, or combinations thereof.
- Some examples of the bioactive agent that can be included in the coating or medical device include, but are not limited to, paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
- The medical device having the features described herein can be used for treating, preventing, or ameliorating a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
- As used herein, the term “antioxidant” refers to a substance that is capable of inhibiting, preventing, reducing or ameliorating oxidative reactions on another substance (e.g., a polymer, a bioactive agent or a therapeutic substance) when the antioxidant is used in a system (e.g., coating) that includes such other substances. An example of such “antioxidant” is oxygen scavenger.
- The antioxidant useful in the present invention can be any volatile or non-volatile antioxidant, which can be natural or synthetic. Natural antioxidant refers to an antioxidant derived from a natural source, with or without modification. Synthetic antioxidant refers to any antioxidant that is not a natural antioxidant. For example, ascorbic acid (Vitamin C) can be a natural antioxidant. BHT, BHA, or a SODm can be a synthetic antioxidant.
- In some embodiments, the antioxidant includes, but is not limited to, BHT, BHA, ascorbic acid (Vitamin C), folic acid, b vitamins, beta carotene, flavonoids, SODm, polyphenol antioxidants such as apigenin or combinations thereof.
- In some embodiments, the term “antioxidant” can specifically exclude an antioxidant described above. For example, the term “antioxidant” can specifically exclude BHT, BHA or a SODm. In some embodiments, the term “antioxidant” can specifically exclude Vitamin E. In some embodiments, the term “antioxidant” can specifically exclude a super-oxide dismutase mimetic (SODm). In still some embodiments, the antioxidant can specifically exclude one of folic acid, b vitamins, beta carotene, flavonoids, polyphenol antioxidants such as apigenin or combinations thereof.
- In some embodiments, a coating or device can include a super-oxide dismutase (SOD) mimetic (SODm). In some embodiments, the SODm can be attached to the surface of a coating or device. The SODm can be attached to the surface of a coating or device via covalent bonding or non-covalent bonding. Non-covalent bonding can be, e.g., ionic interaction, hydrogen bonding, or an interpenetrating network (IPN).
- As used herein, the term SODm refers to any super-oxide dismutase (SOD) mimetic. SOD can have important effects on vascular pathophysiology. For example, SOD1-deficient mice have been found to produce more superoxide than their wild-type controls and have decreased endothelium-dependent and -independent vasodilation. SOD1 overexpression in mice causes a decrease in VSMC proliferation in response to EGF but no change in the aortic hypertrophic response to Angiotensin II. A separate study with mice overexpressing SOD1 on the apoE−/− background showed no significant effect on aortic atherosclerotic lesion area. Total SOD2 deficiency is lethal in mice, and although partial SOD2 deficiency has been shown to cause an increase in atherosclerotic lesion formation at arterial branch points, there was no effect on vasomotor responses to serotonin, PGF2α, or acetylcholine at baseline or after inhibition of SOD1 and SOD3 with diethyldithiocarbamate. The second most abundant SOD isoform in blood vessels is SOD3, which is predominantly produced by VSMCs, but because of its location in the interstitium between ECs and VSMCs, it is thought to be essential for endothelial-dependent vasodilation by protecting NO as it diffuses from the ECs to the VSMCs. These differences in the regulation of vascular tone or in the formation of atherosclerotic lesions indicate the potential importance of the subcellular localization of antioxidant systems in the modulation of local oxidant signaling.
- Some examples of SODm include, but are not limited to, low molecular weight SOD synzymes having a Mn(II) coordinated in a macrocyclic pentamine ring (Ref: Riley D P, Weiss R H. JACS 1994; 116:387-388). In some embodiments, a coating or device can specifically exclude a SODm described above.
- A SODm can be included in the coating or device or attached to the surface of a coating or device with or without a spacer. Attaching a SODm to the surface of a coating or device can be achieved by, for example, attaching the SODm to a polymer on the surface of the coating or the device via coupling of the reactive group in the SODm molecule to the polymer. In some embodiments, attaching a SODm to the polymer can be achieved by photo or thermally initiated radical coupling, which are well known in the art. In some embodiments, covalent attachment of a SODm to a polymer in the coating can be accomplished for example by reacting isocyanate group on the polymer chain with amino group on SODm (ref. Udipi, K, et al. J. biomaterial Mater. Res., 51, 549-560, 2000).
- In some embodiments, attachment of a SODm to the polymer can be induced via photo activation. For example, photo-reactive chemical(s) (PRC) can extract hydrogen on the surface in the form of C—H or Si—H bonds, and covalently couple directly to the surface. If the PRC contains chemically reactive groups, a SODm, can be bound to the PRC. As a result, a SODm can be covalently grafted to the carbon surface.
- Examples of photo-reactive chemicals are from the benzophenone family, i.e. benzophenone tetracarboxylic dianhydride, benzoylbenzoic acid, benzoyl benzoyl chloride, 4-benzoylbenzoic acid N-hydroxysuccinimide ester, benzoyl benzoyl amine, or from azide family, i.e. substituted phenyl azide and substituted acyl azide.
- The hydrogen extraction can be initiated by UV exposure of the PRC entity. The linking reaction between PRC to the SODm will be dependent on the specific structure of the molecule but can be readily carried out by an ordinary artisan. For example, an amine functional group on SODm can react with an anhydride or acyl chloride of substituted benzophenone. The PRC can be coupled to the carbon surface first and then coupled with the SODm, or vice versa.
- In some embodiments, a SODm can be attached to a polymer to form a SODm/polymer conjugate. The SODm/polymer conjugate can then be included in a formulation for forming a coating or a device. The SODm/polymer conjugate can have a covalent bond or non-covalent bond between the SODm and the polymer.
- In some embodiments, antioxidants can be susceptible to oxidation or chemical changes under certain conditions. For example, BHT and BHA at an elevated temperature can compromise the molecular integrity of the antioxidant or cause an volatile antioxidant to evaporate. Therefore, the conditions in the coating process or device forming process can affect the content of the antioxidant to minimize the reduction of the level of antioxidant.
- In some embodiments, the loss of antioxidant(s) in the coating or device forming process can be reduced by controlling the processing conditions. Such control of processing conditions can be, e.g., duration of the process, exclusion of air or oxygen using inert atmosphere or lowering the processing temperature. In some embodiments, the sterilization process can be conducted at a low temperature. A low temperature of sterilization refers to a temperature from about 25° C. to about 55° C., e.g., from about 30° C. to about 45° C. In some embodiments, the baking process can be conducted at a low temperature or in vacuum. A low temperature of baking refers to a temperature from about 25° C. to about 55° C. with and without vacumm. The procedure or process of coating or forming a medical device including stent is well documented in the art.
- In some embodiments, the content of the antioxidant in a coating or device can be maintained or enhanced by adding an additional amount of the antioxidant (e.g., BHT or BHA) in the formulation forming the coating or device. Such additional amount depends from the chemical, physical or physiological nature of the antioxidant. For example, in the coating formulation, the BHT level can be increased up to about 60 wt %. Other types of antioxidant such as vitamin C can have a level from about 60 wt %. If a coating already contains an active agent, the antioxidant can be added as a second active agent in the coating at an amount that can be up to about 50 wt %. The active agent can be, e.g., paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor-cell-capturing antibody, or combinations thereof.
- A coating or device having an antioxidant described herein can include one or more biocompatible polymer(s). The biocompatible polymer can be biodegradable (bioerodable or bioabsorbable) or nondegradable. Representative biocompatible polymers include, but are not limited to, poly(ester amide), polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(3-hydroxyheptanoate) and poly(3-hydroxyoctanoate), poly(4-hydroxyalkanaote) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanote), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate or 4-hydroxyalkanoate monomers described herein or blends thereof, poly(D,L-lactide), poly(L-lactide), polyglycolide, poly(D,L-lactide-co-glycolide), poly(L-lactide-co-glycolide), polycaprolactone, poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(dioxanone), poly(ortho esters), poly(anhydrides), poly(tyrosine carbonates) and derivatives thereof, poly(tyrosine ester) and derivatives thereof, poly(imino carbonates), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyurethanes, polyphosphazenes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride, polyvinyl ethers, such as polyvinyl methyl ether, polyvinylidene halides, such as polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate, copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, polycarbonates, polyoxymethylenes, polyimides, polyethers, poly(glyceryl sebacate), poly(propylene fumarate), poly(n-butyl methacrylate), poly(sec-butyl methacrylate), poly(isobutyl methacrylate), poly(tert-butyl methacrylate), poly(n-propyl methacrylate), poly(isopropyl methacrylate), poly(ethyl methacrylate), poly(methyl methacrylate), epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, carboxymethyl cellulose, polyethers such as poly(ethylene glycol) (PEG), copoly(ether-esters) (e.g. PEO/PLA), polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as HEMA, hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as collagen, chitosan, alginate, fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, or combinations thereof. In some embodiments, the coating or device described herein can exclude any one of the aforementioned polymers.
- As used herein, the terms poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-glycolide), and poly(L-lactide-co-glycolide) can be used interchangeably with the terms poly(D,L-lactic acid), poly(L-lactic acid), poly(D,L-lactic acid-co-glycolic acid), or poly(L-lactic acid-co-glycolic acid), respectively.
- In some embodiments, the coating or device can include a fluoropolymer such as a Solef™ polymer (e.g., PVDF-HFP).
- In some embodiments, the coating or device can further include a biobeneficial material. The biobeneficial material can be polymeric or non-polymeric. The biobeneficial material is preferably substantially non-toxic, non-antigenic and non-immunogenic. A biobeneficial material is one that enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non-thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent.
- Representative biobeneficial materials include, but are not limited to, polyethers such as poly(ethylene glycol), copoly(ether-esters) (e.g. PEO/PLA), polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, poly(ethylene glycol) acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen, dextran, dextrin, hyaluronic acid, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, elastin, chitosan, alginate, silicones, PolyActive™, and combinations thereof. In some embodiments, the coating or device can exclude any one of the aforementioned polymers.
- The term PolyActive™ refers to a block copolymer having flexible poly(ethylene glycol) and poly(butylene terephthalate) blocks (PEGT/PBT). PolyActive™ is intended to include AB, ABA, BAB copolymers having such segments of PEG and PBT (e.g., poly(ethylene glycol)-block-poly(butyleneterephthalate)-block poly(ethylene glycol) (PEG-PBT-PEG).
- In a preferred embodiment, the biobeneficial material can be a polyether such as poly(ethylene glycol) (PEG) or polyalkylene oxide.
- Above listed polymers can be used as a drug carrier for active agents or topcoat to control the drug release. Alternatively, one active agent (such as antioxidant) can be imbedded in one biocompatible coating and another active agent (anti-proliferative agent) can be coated with the polymer on the top of the layer or vice versa.
- In some embodiments, the coating or device having the features described herein can include one or more bioactive agents. The bioactive agents can be any bioactive agent that is therapeutic, prophylactic, or diagnostic. These agents can have anti-proliferative or anti-inflammatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, and antioxidant properties. These agents can be cystostatic agents, agents that promote the healing of the endothelium such as NO releasing or generating agents, agents that attract endothelial progenitor cells, or agents that promote the attachment, migration and proliferation of endothelial cells (e.g., natriuretic peptide such as CNP, ANP or BNP peptide or an RGD or cRGD peptide), while quenching smooth muscle cell proliferation. Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules that bind to complementary DNA to inhibit transcription, and ribozymes. Some other examples of other bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Examples of anti-proliferative agents include rapamycin and its functional or structural derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), and its functional or structural derivatives, paclitaxel and its functional and structural derivatives. Examples of rapamycin derivatives include methyl rapamycin (ABT-578), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin. Examples of paclitaxel derivatives include docetaxel. Examples of antineoplastics or antimitotics include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ib/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax (Biogen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), nitric oxide or nitric oxide donors, super oxide dismutases, super oxide dismutase mimetic, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), estradiol, anticancer agents, dietary supplements such as various vitamins, and a combination thereof. Examples of anti-inflammatory agents including steroidal and non-steroidal anti-inflammatory agents include tacrolimus, dexamethasone, clobetasol, combinations thereof. Examples of such cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.). An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents that may be appropriate include alpha-interferon, pimecrolimus, imatinib mesylate, midostaurin, bioactive RGD, and genetically engineered endothelial cells. The foregoing substances can also be used in the form of prodrugs or co-drugs thereof. The foregoing substances also include metabolites thereof or prodrugs of the metabolites. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents that are currently available or that may be developed in the future are equally applicable.
- The dosage or concentration of the bioactive agent required to produce a favorable therapeutic effect should be less than the level at which the bioactive agent produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the bioactive agent can depend upon factors such as the particular circumstances of the patient, the nature of the trauma, the nature of the therapy desired, the time over which the ingredient administered resides at the vascular site, and if other active agents are employed, the nature and type of the substance or combination of substances. Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
- As used herein, a medical device may be any suitable medical substrate that can be implanted in a human or veterinary patient. Examples of such medical devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), heart valve prostheses, cerebrospinal fluid shunts, pacemaker electrodes, catheters, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, Calif.), anastomotic devices and connectors, orthopedic implants such as screws, spinal implants, and electro-stimulatory devices. The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable (e.g., bioabsorbable stent) or biostable polymers could also be used with the embodiments of the present invention.
- Preferably, the medical device is a stent. The stent described herein is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating is particularly useful for treating diseased regions of blood vessels caused by lipid deposition, monocyte or macrophage infiltration, or dysfunctional endothelium or a combination thereof, or occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis. Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, carotid and coronary arteries.
- For implantation of a stent, an angiogram is first performed to determine the appropriate positioning for stent therapy. An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an artery or vein as an x-ray is taken. A guidewire is then advanced through the lesion or proposed site of treatment. Over the guidewire is passed a delivery catheter that allows a stent in its collapsed configuration to be inserted into the passageway. The delivery catheter is inserted either percutaneously or by surgery into the femoral artery, radial artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance. A stent having the above-described coating may then be expanded at the desired area of treatment. A post-insertion angiogram may also be utilized to confirm appropriate positioning.
- While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
Claims (51)
1. A medical device comprising a coating, the coating comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof,
wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and
wherein the natural antioxidant is not Vitamin E.
2. The medical device of claim 1 , wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.
3. The medical device of claim 2 , wherein the SODm is attached to the surface of the coating.
4. The medical device of claim 3 , wherein the SODm is attached to a polymer in the coating.
5. The medical device of claim 1 , wherein the coating further comprises a bioactive agent.
6. The medical device of claim 1 , wherein the coating further comprises heparin.
7. The medical device of claim 5 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
8. The medical device of claim 1 , which is a stent.
9. The medical device of claim 1 , which is a bioabsorbable stent.
10. The medical device of claim 1 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
11. A bioabsorbable medical device comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof,
wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and
wherein the natural antioxidant is not Vitamin E.
12. The bioabsorbable medical device of claim 11 , wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.
13. The bioabsorbable medical device of claim 11 , wherein the SODm is attached to the surface of the bioabsorbable medical device.
14. The bioabsorbable medical device of claim 11 , wherein the bioabsorbable medical device further comprises a bioactive agent.
15. The bioabsorbable medical device of claim 11 , wherein the bioabsorbable medical device further comprises heparin.
16. The medical device of claim 14 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
17. The bioabsorbable medical device of claim 11 , which is a stent.
18. The bioabsorbable medical device of claim 11 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
19. A method comprising
applying to a medical device a formulation comprising an antioxidant selected from natural antioxidants, synthetic antioxidants, or combinations thereof, and
forming a coating of the formulation on the medical device,
wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA),
wherein the synthetic antioxidant is not butylated hydroxytoluene (BHT) or butylated hydroxyanisole (BHA), and
wherein the natural antioxidant is not Vitamin E.
20. The method of claim 19 , wherein the antioxidant is selected from ascorbic acid, folic acid and B vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.
21. The method of claim 20 , wherein the SODm is attached to the surface of the coating.
22. The method of claim 20 , wherein the SODm is attached to a polymer in the coating.
23. The method of claim 19 , wherein the formulation further comprises a bioactive agent.
24. The method of claim 19 , wherein the formulation further comprises heparin.
25. The method of claim 24 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate; midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
26. The method of claim 19 , wherein the medical device is a stent.
27. The method of claim 19 , wherein the medical device is a bioabsorbable stent.
27. The method of claim 19 , wherein forming the coating comprises
baking the coating, and
sterilizing the coating.
28. The method of claim 27 , wherein the baking or sterilizing are conducted at a temperature between about 25° C. and about 55° C.
29. The method of claim 20 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
30. A method comprising implanting the medical device of claim 1 into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
31. A method, comprising implanting the medical device of claim 7 to the human being, into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
32. A method comprising implanting the medical device of claim 8 into a human being in need of treatment for atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
33. A medical device comprising a coating, the coating comprising at least two antioxidants, wherein one antioxidant is selected from BHT, BHA, Vitamin E, a SODm or a combination thereof.
34. The medical device of claim 33 , wherein the other antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, polyphenol antioxidants, apigenin or combinations thereof.
35. The medical device of claim 33 , wherein the SODm is attached to the surface of the coating.
36. The medical device of claim 35 , wherein the SODm is attached to a polymer in the coating.
37. The medical device of claim 33 , wherein the coating further comprises a bioactive agent.
38. The medical device of claim 33 , wherein the coating further comprises heparin.
39. The medical device of claim 37 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
40. The medical device of claim 33 , which is a stent.
41. The medical device of claim 33 , which is a bioabsorbable stent.
42. The medical device of claim 33 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
43. A bioabsorbable medical device comprising at least two antioxidants, wherein one antioxidant is selected from BHT, BHA, Vitamin E, a SODm or a combination thereof.
44. The bioabsorbable medical device of claim 43 , wherein the antioxidant is selected from ascorbic acid, folic acid and b vitamins, beta carotene, flavonoids, a super-oxide dismutase mimetic (SODm), polyphenol antioxidants, apigenin or combinations thereof.
45. The bioabsorbable medical device of claim 43 , wherein the SODm is attached to the surface of the bioabsorbable medical device.
46. The bioabsorbable medical device of claim 43 , wherein the bioabsorbable medical device further comprises a bioactive agent.
47. The bioabsorbable medical device of claim 43 , wherein the bioabsorbable medical device further comprises heparin.
48. The medical device of claim 46 , wherein the bioactive agent is selected from the group consisting of paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
49. The bioabsorbable medical device of claim 43 , which is a stent.
50. The bioabsorbable medical device of claim 43 , wherein the SODm comprises a Mn(II) coordinated in a macrocyclic pentamine ring.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/528,891 US20070198080A1 (en) | 2005-07-25 | 2006-09-27 | Coatings including an antioxidant |
US12/485,756 US8394446B2 (en) | 2005-07-25 | 2009-06-16 | Methods of providing antioxidants to implantable medical devices |
US13/759,898 US9655751B2 (en) | 2005-07-25 | 2013-02-05 | Kits including implantable medical devices and antioxidants |
US13/760,540 US20130145729A1 (en) | 2005-07-25 | 2013-02-06 | Methods of Providing Antioxidants to Implantable Medical Devices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/189,216 US7785647B2 (en) | 2005-07-25 | 2005-07-25 | Methods of providing antioxidants to a drug containing product |
US11/528,891 US20070198080A1 (en) | 2005-07-25 | 2006-09-27 | Coatings including an antioxidant |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/189,216 Continuation-In-Part US7785647B2 (en) | 2005-07-25 | 2005-07-25 | Methods of providing antioxidants to a drug containing product |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/189,216 Continuation-In-Part US7785647B2 (en) | 2005-07-25 | 2005-07-25 | Methods of providing antioxidants to a drug containing product |
US12/485,756 Continuation-In-Part US8394446B2 (en) | 2005-07-25 | 2009-06-16 | Methods of providing antioxidants to implantable medical devices |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070198080A1 true US20070198080A1 (en) | 2007-08-23 |
Family
ID=37679362
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/189,216 Expired - Fee Related US7785647B2 (en) | 2005-07-25 | 2005-07-25 | Methods of providing antioxidants to a drug containing product |
US11/528,891 Abandoned US20070198080A1 (en) | 2005-07-25 | 2006-09-27 | Coatings including an antioxidant |
US12/851,420 Expired - Fee Related US9675737B2 (en) | 2005-07-25 | 2010-08-05 | Methods of providing antioxidants to a drug containing product |
US12/851,414 Abandoned US20100300917A1 (en) | 2005-07-25 | 2010-08-05 | Methods of providing antioxidants to a drug containing product |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/189,216 Expired - Fee Related US7785647B2 (en) | 2005-07-25 | 2005-07-25 | Methods of providing antioxidants to a drug containing product |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/851,420 Expired - Fee Related US9675737B2 (en) | 2005-07-25 | 2010-08-05 | Methods of providing antioxidants to a drug containing product |
US12/851,414 Abandoned US20100300917A1 (en) | 2005-07-25 | 2010-08-05 | Methods of providing antioxidants to a drug containing product |
Country Status (2)
Country | Link |
---|---|
US (4) | US7785647B2 (en) |
WO (1) | WO2007018931A2 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080114096A1 (en) * | 2006-11-09 | 2008-05-15 | Hydromer, Inc. | Lubricious biopolymeric network compositions and methods of making same |
US20100280594A1 (en) * | 2009-05-01 | 2010-11-04 | Medi-Solve, Llc | Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto |
US20100300917A1 (en) * | 2005-07-25 | 2010-12-02 | Ni Ding | Methods of providing antioxidants to a drug containing product |
US20110137407A1 (en) * | 2009-07-09 | 2011-06-09 | Thai Minh Nguyen | Bare metal stent with drug eluting reservoirs |
US8128688B2 (en) * | 2006-06-27 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Carbon coating on an implantable device |
US8366660B2 (en) | 2006-11-20 | 2013-02-05 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8366662B2 (en) | 2006-11-20 | 2013-02-05 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US20130192167A1 (en) * | 2010-09-17 | 2013-08-01 | Terumo Kabushiki Kaisha | Silicone rubber composition |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9402935B2 (en) | 2006-11-20 | 2016-08-02 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
RU2606436C2 (en) * | 2012-03-13 | 2017-01-10 | ТиссенКрупп Рассельштайн ГмбХ | Method for treating steel band or plate provided with metal coating with after-treatment agent, and steel band or plate provided with metal coating |
US9655751B2 (en) | 2005-07-25 | 2017-05-23 | Abbott Cardiovascular Systems Inc. | Kits including implantable medical devices and antioxidants |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9901663B2 (en) | 2013-05-06 | 2018-02-27 | Abbott Cardiovascular Systems Inc. | Hollow stent filled with a therapeutic agent formulation |
US10485901B2 (en) * | 2015-02-26 | 2019-11-26 | Battelle Memorial Institute | Implant with reactive oxygen species scavenging coating |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7727221B2 (en) | 2001-06-27 | 2010-06-01 | Cardiac Pacemakers Inc. | Method and device for electrochemical formation of therapeutic species in vivo |
US7349971B2 (en) * | 2004-02-05 | 2008-03-25 | Scenera Technologies, Llc | System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information |
US10076641B2 (en) | 2005-05-11 | 2018-09-18 | The Spectranetics Corporation | Methods and systems for delivering substances into luminal walls |
US20070135909A1 (en) * | 2005-12-08 | 2007-06-14 | Desnoyer Jessica R | Adhesion polymers to improve stent retention |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
CA2663271A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
JP2010503489A (en) * | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
EP2125065B1 (en) | 2006-12-28 | 2010-11-17 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making same |
JP2008305262A (en) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | Printer introduction method in server and thin client environment |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20090319031A1 (en) * | 2008-06-19 | 2009-12-24 | Yunbing Wang | Bioabsorbable Polymeric Stent With Improved Structural And Molecular Weight Integrity |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
WO2011119573A1 (en) | 2010-03-23 | 2011-09-29 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
JP5802258B2 (en) * | 2010-03-25 | 2015-10-28 | ルトニックス,インコーポレーテッド | Drug release coating for medical devices |
EP2380605A1 (en) * | 2010-04-19 | 2011-10-26 | InnoRa Gmbh | Improved formulations for drug-coated medical devices |
EP2383000A1 (en) * | 2010-04-19 | 2011-11-02 | InnoRa Gmbh | Limus-coated medical devices |
EP2380604A1 (en) * | 2010-04-19 | 2011-10-26 | InnoRa Gmbh | Improved coating formulations for scoring or cutting balloon catheters |
US8966868B2 (en) * | 2011-05-09 | 2015-03-03 | Abbott Cardiovascular Systems Inc. | Methods of stabilizing molecular weight of polymer stents after sterilization |
CN104039371B (en) | 2011-10-14 | 2016-06-01 | 伊诺拉两合有限公司 | For the improved formulations of medication coat medical treatment device |
WO2013102842A2 (en) | 2012-01-06 | 2013-07-11 | Sahajanand Medical Technologies Private Limited | Device and composition for drug release |
US20140102049A1 (en) * | 2012-10-17 | 2014-04-17 | Abbott Cardiovascular Systems Inc. | Method Of Fabrication Of Implantable Medical Device Comprising Macrocyclic Triene Active Agent And Antioxidant |
Citations (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2072303A (en) * | 1932-10-18 | 1937-03-02 | Chemische Forschungs Gmbh | Artificial threads, bands, tubes, and the like for surgical and other purposes |
US3429717A (en) * | 1965-05-24 | 1969-02-25 | Grace W R & Co | Flexible film wrapper |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US5100992A (en) * | 1989-05-04 | 1992-03-31 | Biomedical Polymers International, Ltd. | Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5298260A (en) * | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
US5380299A (en) * | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
US5485496A (en) * | 1994-09-22 | 1996-01-16 | Cornell Research Foundation, Inc. | Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5607467A (en) * | 1990-09-14 | 1997-03-04 | Froix; Michael | Expandable polymeric stent with memory and delivery apparatus and method |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5610241A (en) * | 1996-05-07 | 1997-03-11 | Cornell Research Foundation, Inc. | Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers |
US5711958A (en) * | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US5721131A (en) * | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
US5723219A (en) * | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US5858746A (en) * | 1992-04-20 | 1999-01-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5857998A (en) * | 1994-06-30 | 1999-01-12 | Boston Scientific Corporation | Stent and therapeutic delivery system |
US5865814A (en) * | 1995-06-07 | 1999-02-02 | Medtronic, Inc. | Blood contacting medical device and method |
US5869127A (en) * | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5873904A (en) * | 1995-06-07 | 1999-02-23 | Cook Incorporated | Silver implantable medical device |
US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US5876433A (en) * | 1996-05-29 | 1999-03-02 | Ethicon, Inc. | Stent and method of varying amounts of heparin coated thereon to control treatment |
US5879713A (en) * | 1994-10-12 | 1999-03-09 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US6010530A (en) * | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
US6011125A (en) * | 1998-09-25 | 2000-01-04 | General Electric Company | Amide modified polyesters |
US6015541A (en) * | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US6034204A (en) * | 1997-08-08 | 2000-03-07 | Basf Aktiengesellschaft | Condensation products of basic amino acids with copolymerizable compounds and a process for their production |
US6033582A (en) * | 1996-01-22 | 2000-03-07 | Etex Corporation | Surface modification of medical implants |
US6037022A (en) * | 1997-09-16 | 2000-03-14 | International Paper Company | Oxygen-scavenging filled polymer blend for food packaging applications |
US6042875A (en) * | 1997-04-30 | 2000-03-28 | Schneider (Usa) Inc. | Drug-releasing coatings for medical devices |
US6172167B1 (en) * | 1996-06-28 | 2001-01-09 | Universiteit Twente | Copoly(ester-amides) and copoly(ester-urethanes) |
US6177523B1 (en) * | 1999-07-14 | 2001-01-23 | Cardiotech International, Inc. | Functionalized polyurethanes |
US6180632B1 (en) * | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6203551B1 (en) * | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6335029B1 (en) * | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US20020007215A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007213A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020005206A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20020007214A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6344035B1 (en) * | 1998-04-27 | 2002-02-05 | Surmodics, Inc. | Bioactive agent release coating |
US6358556B1 (en) * | 1995-04-19 | 2002-03-19 | Boston Scientific Corporation | Drug release stent coating |
US20030004141A1 (en) * | 2001-03-08 | 2003-01-02 | Brown David L. | Medical devices, compositions and methods for treating vulnerable plaque |
US6503538B1 (en) * | 2000-08-30 | 2003-01-07 | Cornell Research Foundation, Inc. | Elastomeric functional biodegradable copolyester amides and copolyester urethanes |
US6503954B1 (en) * | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US6503556B2 (en) * | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US6506437B1 (en) * | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US20030028243A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US20030028244A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US20030032767A1 (en) * | 2001-02-05 | 2003-02-13 | Yasuhiro Tada | High-strength polyester-amide fiber and process for producing the same |
US20030036794A1 (en) * | 1995-06-07 | 2003-02-20 | Cook Incorporated | Coated implantable medical device |
US6524347B1 (en) * | 1997-05-28 | 2003-02-25 | Avantis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20030039689A1 (en) * | 2001-04-26 | 2003-02-27 | Jianbing Chen | Polymer-based, sustained release drug delivery system |
US6527863B1 (en) * | 2001-06-29 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Support device for a stent and a method of using the same to coat a stent |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US20030059520A1 (en) * | 2001-09-27 | 2003-03-27 | Yung-Ming Chen | Apparatus for regulating temperature of a composition and a method of coating implantable devices |
US20030060877A1 (en) * | 2001-09-25 | 2003-03-27 | Robert Falotico | Coated medical devices for the treatment of vascular disease |
US6673154B1 (en) * | 2001-06-28 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Stent mounting device to coat a stent |
US6673385B1 (en) * | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US20040018296A1 (en) * | 2000-05-31 | 2004-01-29 | Daniel Castro | Method for depositing a coating onto a surface of a prosthesis |
US6689350B2 (en) * | 2000-07-27 | 2004-02-10 | Rutgers, The State University Of New Jersey | Therapeutic polyesters and polyamides |
US6689099B2 (en) * | 1999-07-13 | 2004-02-10 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
US20040029952A1 (en) * | 1999-09-03 | 2004-02-12 | Yung-Ming Chen | Ethylene vinyl alcohol composition and coating |
US6695920B1 (en) * | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US20040047980A1 (en) * | 2000-12-28 | 2004-03-11 | Pacetti Stephen D. | Method of forming a diffusion barrier layer for implantable devices |
US20040047978A1 (en) * | 2000-08-04 | 2004-03-11 | Hossainy Syed F.A. | Composition for coating an implantable prosthesis |
US6706013B1 (en) * | 2001-06-29 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Variable length drug delivery catheter |
US20040052859A1 (en) * | 2001-05-09 | 2004-03-18 | Wu Steven Z. | Microparticle coated medical device |
US20040054104A1 (en) * | 2002-09-05 | 2004-03-18 | Pacetti Stephen D. | Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol) |
US6709514B1 (en) * | 2001-12-28 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Rotary coating apparatus for coating implantable medical devices |
US6712845B2 (en) * | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US6713119B2 (en) * | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US20050004663A1 (en) * | 2001-05-07 | 2005-01-06 | Llanos Gerard H. | Heparin barrier coating for controlled drug release |
US20050038497A1 (en) * | 2003-08-11 | 2005-02-17 | Scimed Life Systems, Inc. | Deformation medical device without material deformation |
US20050037052A1 (en) * | 2003-08-13 | 2005-02-17 | Medtronic Vascular, Inc. | Stent coating with gradient porosity |
US20050038134A1 (en) * | 1997-08-18 | 2005-02-17 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
US20050037048A1 (en) * | 2003-08-11 | 2005-02-17 | Young-Ho Song | Medical devices containing antioxidant and therapeutic agent |
US20050043786A1 (en) * | 2003-08-18 | 2005-02-24 | Medtronic Ave, Inc. | Methods and apparatus for treatment of aneurysmal tissue |
US6861088B2 (en) * | 2002-03-28 | 2005-03-01 | Boston Scientific Scimed, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US20050049693A1 (en) * | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
US20050049694A1 (en) * | 2003-08-07 | 2005-03-03 | Medtronic Ave. | Extrusion process for coating stents |
US20050055078A1 (en) * | 2003-09-04 | 2005-03-10 | Medtronic Vascular, Inc. | Stent with outer slough coating |
US20050055044A1 (en) * | 2003-09-09 | 2005-03-10 | Scimed Life Systems, Inc. | Lubricious coatings for medical device |
US20050054774A1 (en) * | 2003-09-09 | 2005-03-10 | Scimed Life Systems, Inc. | Lubricious coating |
US6865810B2 (en) * | 2002-06-27 | 2005-03-15 | Scimed Life Systems, Inc. | Methods of making medical devices |
US20050060020A1 (en) * | 2003-09-17 | 2005-03-17 | Scimed Life Systems, Inc. | Covered stent with biologically active material |
US6869443B2 (en) * | 1991-10-04 | 2005-03-22 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US20050064088A1 (en) * | 2003-09-24 | 2005-03-24 | Scimed Life Systems, Inc | Ultrasonic nozzle for coating a medical appliance and method for using an ultrasonic nozzle to coat a medical appliance |
US20050065545A1 (en) * | 2003-09-23 | 2005-03-24 | Scimed Life Systems, Inc. | External activation of vaso-occlusive implants |
US20050065501A1 (en) * | 2003-09-23 | 2005-03-24 | Scimed Life Systems, Inc. | Energy activated vaso-occlusive devices |
US20050065593A1 (en) * | 2003-09-19 | 2005-03-24 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
Family Cites Families (231)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2386454A (en) | 1940-11-22 | 1945-10-09 | Bell Telephone Labor Inc | High molecular weight linear polyester-amides |
US3849514A (en) | 1967-11-17 | 1974-11-19 | Eastman Kodak Co | Block polyester-polyamide copolymers |
US3993622A (en) * | 1970-10-08 | 1976-11-23 | Ciba-Geigy Corporation | Bis-salicyloyl-hydrazine as stabilizer for polymers |
US3773737A (en) | 1971-06-09 | 1973-11-20 | Sutures Inc | Hydrolyzable polymers of amino acid and hydroxy acids |
US4329383A (en) | 1979-07-24 | 1982-05-11 | Nippon Zeon Co., Ltd. | Non-thrombogenic material comprising substrate which has been reacted with heparin |
US4226243A (en) | 1979-07-27 | 1980-10-07 | Ethicon, Inc. | Surgical devices of polyesteramides derived from bis-oxamidodiols and dicarboxylic acids |
SU790725A1 (en) | 1979-07-27 | 1983-01-23 | Ордена Ленина Институт Элементоорганических Соединений Ан Ссср | Process for preparing alkylaromatic polyimides |
SU811750A1 (en) | 1979-08-07 | 1983-09-23 | Институт Физиологии Им.С.И.Бериташвили | Bis-bicarbonates of aliphatic diols as monomers for preparing polyurethanes and process for producing the same |
SU872531A1 (en) | 1979-08-07 | 1981-10-15 | Институт Физиологии Им.И.С.Бериташвили Ан Гсср | Method of producing polyurethans |
SU876663A1 (en) | 1979-11-11 | 1981-10-30 | Институт Физиологии Им. Академика И.С.Бериташвили Ан Гсср | Method of producing polyarylates |
US4529792A (en) | 1979-12-17 | 1985-07-16 | Minnesota Mining And Manufacturing Company | Process for preparing synthetic absorbable poly(esteramides) |
SU1016314A1 (en) | 1979-12-17 | 1983-05-07 | Институт Физиологии Им.И.С.Бериташвили | Process for producing polyester urethanes |
US4343931A (en) | 1979-12-17 | 1982-08-10 | Minnesota Mining And Manufacturing Company | Synthetic absorbable surgical devices of poly(esteramides) |
SU905228A1 (en) | 1980-03-06 | 1982-02-15 | Институт Физиологии Им. Акад.И.С. Бериташвили Ан Гсср | Method for preparing thiourea |
US4401804A (en) * | 1982-05-24 | 1983-08-30 | Eastman Kodak Company | Deactivation of polyester catalyst residues |
US5006281A (en) * | 1985-03-26 | 1991-04-09 | Century Laboratories, Inc. | Process for the production of a marine animal oil |
SU1293518A1 (en) | 1985-04-11 | 1987-02-28 | Тбилисский зональный научно-исследовательский и проектный институт типового и экспериментального проектирования жилых и общественных зданий | Installation for testing specimen of cross-shaped structure |
US4656242A (en) | 1985-06-07 | 1987-04-07 | Henkel Corporation | Poly(ester-amide) compositions |
US4611051A (en) | 1985-12-31 | 1986-09-09 | Union Camp Corporation | Novel poly(ester-amide) hot-melt adhesives |
US4882168A (en) | 1986-09-05 | 1989-11-21 | American Cyanamid Company | Polyesters containing alkylene oxide blocks as drug delivery systems |
JPH0696023B2 (en) | 1986-11-10 | 1994-11-30 | 宇部日東化成株式会社 | Artificial blood vessel and method for producing the same |
US6387379B1 (en) | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
US5527337A (en) * | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
US4894231A (en) | 1987-07-28 | 1990-01-16 | Biomeasure, Inc. | Therapeutic agent delivery system |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5019096A (en) | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
JP2561309B2 (en) | 1988-03-28 | 1996-12-04 | テルモ株式会社 | Medical material and manufacturing method thereof |
US4931287A (en) | 1988-06-14 | 1990-06-05 | University Of Utah | Heterogeneous interpenetrating polymer networks for the controlled release of drugs |
US5328471A (en) | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
US4977901A (en) | 1988-11-23 | 1990-12-18 | Minnesota Mining And Manufacturing Company | Article having non-crosslinked crystallized polymer coatings |
US5272012A (en) | 1989-06-23 | 1993-12-21 | C. R. Bard, Inc. | Medical apparatus having protective, lubricious coating |
US5971954A (en) | 1990-01-10 | 1999-10-26 | Rochester Medical Corporation | Method of making catheter |
US5496557A (en) | 1990-01-30 | 1996-03-05 | Akzo N.V. | Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances |
US5306501A (en) | 1990-05-01 | 1994-04-26 | Mediventures, Inc. | Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers |
US5300295A (en) | 1990-05-01 | 1994-04-05 | Mediventures, Inc. | Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH |
AU7998091A (en) | 1990-05-17 | 1991-12-10 | Harbor Medical Devices, Inc. | Medical device polymer |
CA2038605C (en) | 1990-06-15 | 2000-06-27 | Leonard Pinchuk | Crack-resistant polycarbonate urethane polymer prostheses and the like |
US6060451A (en) | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
WO1991019529A1 (en) | 1990-06-15 | 1991-12-26 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
US5112457A (en) | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
US5455040A (en) | 1990-07-26 | 1995-10-03 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
US5163952A (en) | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US6248129B1 (en) | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
GB9027793D0 (en) | 1990-12-21 | 1991-02-13 | Ucb Sa | Polyester-amides containing terminal carboxyl groups |
US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
GB9206736D0 (en) | 1992-03-27 | 1992-05-13 | Sandoz Ltd | Improvements of organic compounds and their use in pharmaceutical compositions |
US5219980A (en) | 1992-04-16 | 1993-06-15 | Sri International | Polymers biodegradable or bioerodiable into amino acids |
US5417981A (en) | 1992-04-28 | 1995-05-23 | Terumo Kabushiki Kaisha | Thermoplastic polymer composition and medical devices made of the same |
DE4224401A1 (en) | 1992-07-21 | 1994-01-27 | Pharmatech Gmbh | New biodegradable homo- and co-polymer(s) for pharmaceutical use - produced by polycondensation of prod. from heterolytic cleavage of aliphatic polyester with functionalised (cyclo)aliphatic cpd. |
US5338822A (en) * | 1992-10-02 | 1994-08-16 | Cargill, Incorporated | Melt-stable lactide polymer composition and process for manufacture thereof |
FR2699168B1 (en) | 1992-12-11 | 1995-01-13 | Rhone Poulenc Chimie | Method of treating a material comprising a polymer by hydrolysis. |
EP0604022A1 (en) | 1992-12-22 | 1994-06-29 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method for its manufacture |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US20020055710A1 (en) | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
US5824048A (en) | 1993-04-26 | 1998-10-20 | Medtronic, Inc. | Method for delivering a therapeutic substance to a body lumen |
JPH0767895A (en) | 1993-06-25 | 1995-03-14 | Sumitomo Electric Ind Ltd | Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation |
EG20321A (en) | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
GB2281161B (en) | 1993-08-04 | 1997-05-28 | Fulcrum Communications Limited | Optical data communications networks |
DE4327024A1 (en) | 1993-08-12 | 1995-02-16 | Bayer Ag | Thermoplastically processable and biodegradable aliphatic polyesteramides |
WO1995010989A1 (en) | 1993-10-19 | 1995-04-27 | Scimed Life Systems, Inc. | Intravascular stent pump |
US5723004A (en) | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
US5759205A (en) | 1994-01-21 | 1998-06-02 | Brown University Research Foundation | Negatively charged polymeric electret implant |
US6051576A (en) | 1994-01-28 | 2000-04-18 | University Of Kentucky Research Foundation | Means to achieve sustained release of synergistic drugs by conjugation |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US5567410A (en) | 1994-06-24 | 1996-10-22 | The General Hospital Corporation | Composotions and methods for radiographic imaging |
US5670558A (en) | 1994-07-07 | 1997-09-23 | Terumo Kabushiki Kaisha | Medical instruments that exhibit surface lubricity when wetted |
US5788979A (en) | 1994-07-22 | 1998-08-04 | Inflow Dynamics Inc. | Biodegradable coating with inhibitory properties for application to biocompatible materials |
US5516881A (en) | 1994-08-10 | 1996-05-14 | Cornell Research Foundation, Inc. | Aminoxyl-containing radical spin labeling in polymers and copolymers |
US5578073A (en) | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
US5649977A (en) | 1994-09-22 | 1997-07-22 | Advanced Cardiovascular Systems, Inc. | Metal reinforced polymer stent |
FR2724938A1 (en) | 1994-09-28 | 1996-03-29 | Lvmh Rech | POLYMERS FUNCTIONALIZED BY AMINO ACIDS OR AMINO ACID DERIVATIVES, THEIR USE AS SURFACTANTS, IN PARTICULAR, IN COSMETIC COMPOSITIONS AND IN PARTICULAR NAIL POLISH. |
US5637113A (en) | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5569198A (en) | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
US5919570A (en) | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US6017577A (en) | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5702754A (en) | 1995-02-22 | 1997-12-30 | Meadox Medicals, Inc. | Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings |
US5854376A (en) | 1995-03-09 | 1998-12-29 | Sekisui Kaseihin Kogyo Kabushiki Kaisha | Aliphatic ester-amide copolymer resins |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US20020091433A1 (en) | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
RU2169742C2 (en) | 1995-04-19 | 2001-06-27 | Катаока Казунори | Heterotelochelate block copolymer and method of preparation thereof |
US5674242A (en) | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
US5667767A (en) | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
US5658995A (en) | 1995-11-27 | 1997-08-19 | Rutgers, The State University | Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide) |
DE19545678A1 (en) | 1995-12-07 | 1997-06-12 | Goldschmidt Ag Th | Copolymers of polyamino acid esters |
EP2111876B1 (en) | 1995-12-18 | 2011-09-07 | AngioDevice International GmbH | Crosslinked polymer compositions and methods for their use |
US5618866A (en) | 1996-01-22 | 1997-04-08 | General Electric Company | Neo diol phosphite esters and polymeric compositions thereof |
US6054553A (en) | 1996-01-29 | 2000-04-25 | Bayer Ag | Process for the preparation of polymers having recurring agents |
US5932299A (en) | 1996-04-23 | 1999-08-03 | Katoot; Mohammad W. | Method for modifying the surface of an object |
US5955509A (en) | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
US5874165A (en) | 1996-06-03 | 1999-02-23 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto polymeric subtrates |
SE9602352D0 (en) | 1996-06-14 | 1996-06-14 | Astra Ab | Catheter package |
US5830178A (en) | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
US6060518A (en) | 1996-08-16 | 2000-05-09 | Supratek Pharma Inc. | Polymer compositions for chemotherapy and methods of treatment using the same |
US5783657A (en) | 1996-10-18 | 1998-07-21 | Union Camp Corporation | Ester-terminated polyamides of polymerized fatty acids useful in formulating transparent gels in low polarity liquids |
US6120491A (en) | 1997-11-07 | 2000-09-19 | The State University Rutgers | Biodegradable, anionic polymers derived from the amino acid L-tyrosine |
US5980972A (en) | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5997517A (en) | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
AU6252298A (en) | 1997-01-28 | 1998-08-18 | United States Surgical Corporation | Polyesteramides with amino acid-derived groups alternating with alpha-hydroxyacid-derived groups and surgical articles made therefrom |
AU6254498A (en) | 1997-01-28 | 1998-08-18 | United States Surgical Corporation | Polyesteramide, its preparation and surgical devices fabricated therefrom |
CA2278613A1 (en) | 1997-01-28 | 1998-07-30 | United States Surgical Corporation | Polyesteramide, its preparation and surgical devices fabricated therefrom |
AU6763998A (en) | 1997-03-20 | 1998-10-12 | Eastman Chemical Company | Process for the modification of a polyester melt used in a continuous melt-to-preform process |
US6240616B1 (en) | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6056993A (en) | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
US6110483A (en) | 1997-06-23 | 2000-08-29 | Sts Biopolymers, Inc. | Adherent, flexible hydrogel and medicated coatings |
US6211249B1 (en) | 1997-07-11 | 2001-04-03 | Life Medical Sciences, Inc. | Polyester polyether block copolymers |
US5980928A (en) | 1997-07-29 | 1999-11-09 | Terry; Paul B. | Implant for preventing conjunctivitis in cattle |
US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US6120788A (en) | 1997-10-16 | 2000-09-19 | Bioamide, Inc. | Bioabsorbable triglycolic acid poly(ester-amide)s |
US5992000A (en) | 1997-10-16 | 1999-11-30 | Scimed Life Systems, Inc. | Stent crimper |
EP1038021A4 (en) * | 1997-12-12 | 2005-02-16 | Jeffrey C Way | Compounds and methods for the inhibition of protein-protein interactions |
US6110188A (en) | 1998-03-09 | 2000-08-29 | Corvascular, Inc. | Anastomosis method |
US6258371B1 (en) | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US7658727B1 (en) | 1998-04-20 | 2010-02-09 | Medtronic, Inc | Implantable medical device with enhanced biocompatibility and biostability |
US20020188037A1 (en) | 1999-04-15 | 2002-12-12 | Chudzik Stephen J. | Method and system for providing bioactive agent release coating |
US6113629A (en) | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
KR100314496B1 (en) | 1998-05-28 | 2001-11-22 | 윤동진 | Non-thrombogenic heparin derivatives, process for preparation and use thereof |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
WO2000010622A1 (en) | 1998-08-20 | 2000-03-02 | Cook Incorporated | Coated implantable medical device |
US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6143354A (en) | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
ES2240101T3 (en) * | 1999-05-27 | 2005-10-16 | Monsanto Company | MODIFIED BIOMATERIALS WITH DISMUTE SUPEROXIDE MIMETICS. |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6494862B1 (en) | 1999-07-13 | 2002-12-17 | Advanced Cardiovascular Systems, Inc. | Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway |
US6759054B2 (en) | 1999-09-03 | 2004-07-06 | Advanced Cardiovascular Systems, Inc. | Ethylene vinyl alcohol composition and coating |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6749626B1 (en) | 2000-03-31 | 2004-06-15 | Advanced Cardiovascular Systems, Inc. | Actinomycin D for the treatment of vascular disease |
US6287628B1 (en) | 1999-09-03 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6379381B1 (en) | 1999-09-03 | 2002-04-30 | Advanced Cardiovascular Systems, Inc. | Porous prosthesis and a method of depositing substances into the pores |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
US20020081228A1 (en) * | 1999-12-21 | 2002-06-27 | Hui Henry K. | Monitoring sterilant concentration in diffusion-restricted regions as a basis for parametric release |
US6613432B2 (en) | 1999-12-22 | 2003-09-02 | Biosurface Engineering Technologies, Inc. | Plasma-deposited coatings, devices and methods |
US6908624B2 (en) | 1999-12-23 | 2005-06-21 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
WO2001047572A2 (en) | 1999-12-29 | 2001-07-05 | Advanced Cardiovascular Systems, Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
WO2001049338A1 (en) | 1999-12-30 | 2001-07-12 | Li Wei Pin | Controlled delivery of therapeutic agents by insertable medical devices |
US6309383B1 (en) | 2000-01-20 | 2001-10-30 | Isostent, Inc. | Stent crimper apparatus with radiation shied |
IT1318423B1 (en) * | 2000-03-24 | 2003-08-25 | Great Lakes Chemical Europ | STABILIZING MIXTURES FOR ORGANIC POLYMERS. |
US6270779B1 (en) | 2000-05-10 | 2001-08-07 | United States Of America | Nitric oxide-releasing metallic medical devices |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US20020022144A1 (en) | 2000-05-19 | 2002-02-21 | Hu Yang | Enhanced oxygen barrier performance from modification of ethylene vinyl alcohol copolymers (EVOH) |
WO2001090331A2 (en) * | 2000-05-23 | 2001-11-29 | The Rockefeller University | C1 bacteriophage lytic system |
DE10025458B4 (en) * | 2000-05-23 | 2005-05-12 | Vacuumschmelze Gmbh | Magnet and method for its production |
US7101624B2 (en) * | 2000-06-22 | 2006-09-05 | Cello-Foil Products, Inc. | Laminate antioxidant film |
US6585765B1 (en) | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US20020077693A1 (en) | 2000-12-19 | 2002-06-20 | Barclay Bruce J. | Covered, coiled drug delivery stent and method |
US6485950B1 (en) * | 2000-07-14 | 2002-11-26 | Council Of Scientific And Industrial Research | Isozyme of autoclavable superoxide dismutase (SOD), a process for the identification and extraction of the SOD in cosmetic, food and pharmaceutical compositions |
US6555157B1 (en) | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
US6585926B1 (en) | 2000-08-31 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a porous balloon |
US6254632B1 (en) | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US20020051730A1 (en) | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US6558733B1 (en) | 2000-10-26 | 2003-05-06 | Advanced Cardiovascular Systems, Inc. | Method for etching a micropatterned microdepot prosthesis |
US6758859B1 (en) | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
US6727300B2 (en) | 2000-11-03 | 2004-04-27 | Cytec Technology Corp. | Polymeric articles containing hindered amine light stabilizers based on multi-functional carbonyl compounds |
US6824559B2 (en) | 2000-12-22 | 2004-11-30 | Advanced Cardiovascular Systems, Inc. | Ethylene-carboxyl copolymers as drug delivery matrices |
US6875400B2 (en) * | 2000-12-22 | 2005-04-05 | Cryovac, Inc. | Method of sterilizing and initiating a scavenging reaction in an article |
US20020082679A1 (en) | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US6544543B1 (en) | 2000-12-27 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Periodic constriction of vessels to treat ischemic tissue |
US6540776B2 (en) | 2000-12-28 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Sheath for a prosthesis and methods of forming the same |
US20020087123A1 (en) | 2001-01-02 | 2002-07-04 | Hossainy Syed F.A. | Adhesion of heparin-containing coatings to blood-contacting surfaces of medical devices |
US6645195B1 (en) | 2001-01-05 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intraventricularly guided agent delivery system and method of use |
US6544223B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Balloon catheter for delivering therapeutic agents |
US6544582B1 (en) | 2001-01-05 | 2003-04-08 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for coating an implantable device |
US20030215564A1 (en) * | 2001-01-18 | 2003-11-20 | Heller Phillip F. | Method and apparatus for coating an endoprosthesis |
US6740040B1 (en) | 2001-01-30 | 2004-05-25 | Advanced Cardiovascular Systems, Inc. | Ultrasound energy driven intraventricular catheter to treat ischemia |
US20040220660A1 (en) * | 2001-02-05 | 2004-11-04 | Shanley John F. | Bioresorbable stent with beneficial agent reservoirs |
WO2002064014A2 (en) | 2001-02-09 | 2002-08-22 | Endoluminal Therapeutics, Inc. | Endomural therapy |
US6613077B2 (en) | 2001-03-27 | 2003-09-02 | Scimed Life Systems, Inc. | Stent with controlled expansion |
US6780424B2 (en) | 2001-03-30 | 2004-08-24 | Charles David Claude | Controlled morphologies in polymer drug for release of drugs from polymer films |
US6623448B2 (en) | 2001-03-30 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Steerable drug delivery device |
US6645135B1 (en) | 2001-03-30 | 2003-11-11 | Advanced Cardiovascular Systems, Inc. | Intravascular catheter device and method for simultaneous local delivery of radiation and a therapeutic substance |
US6625486B2 (en) | 2001-04-11 | 2003-09-23 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for intracellular delivery of an agent |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US6660034B1 (en) | 2001-04-30 | 2003-12-09 | Advanced Cardiovascular Systems, Inc. | Stent for increasing blood flow to ischemic tissues and a method of using the same |
US7651695B2 (en) | 2001-05-18 | 2010-01-26 | Advanced Cardiovascular Systems, Inc. | Medicated stents for the treatment of vascular disease |
US7862495B2 (en) | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US6605154B1 (en) | 2001-05-31 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stent mounting device |
US6743462B1 (en) | 2001-05-31 | 2004-06-01 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for coating implantable devices |
US6666880B1 (en) | 2001-06-19 | 2003-12-23 | Advised Cardiovascular Systems, Inc. | Method and system for securing a coated stent to a balloon catheter |
US6572644B1 (en) | 2001-06-27 | 2003-06-03 | Advanced Cardiovascular Systems, Inc. | Stent mounting device and a method of using the same to coat a stent |
US6565659B1 (en) | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
US6585755B2 (en) | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US6656216B1 (en) | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
EP1273314A1 (en) | 2001-07-06 | 2003-01-08 | Terumo Kabushiki Kaisha | Stent |
US6641611B2 (en) | 2001-11-26 | 2003-11-04 | Swaminathan Jayaraman | Therapeutic coating for an intravascular implant |
US20030083739A1 (en) | 2001-09-24 | 2003-05-01 | Robert Cafferata | Rational drug therapy device and methods |
US6753071B1 (en) | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20030065377A1 (en) | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US20030073961A1 (en) | 2001-09-28 | 2003-04-17 | Happ Dorrie M. | Medical device containing light-protected therapeutic agent and a method for fabricating thereof |
US7585516B2 (en) | 2001-11-12 | 2009-09-08 | Advanced Cardiovascular Systems, Inc. | Coatings for drug delivery devices |
US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
US6607795B1 (en) | 2001-12-19 | 2003-08-19 | Chevron Phillips Chemical Company Lp | Oxygen scavenging compositions comprising polymers derived from aromatic difunctional monomers |
US6949254B2 (en) | 2002-01-30 | 2005-09-27 | Bmg Incorporated | Bio-decomposable polymer composition showing good thermal decomposition |
US7445629B2 (en) | 2002-01-31 | 2008-11-04 | Boston Scientific Scimed, Inc. | Medical device for delivering biologically active material |
US6746622B2 (en) | 2002-02-08 | 2004-06-08 | Chevron Phillips Chemical Company Lp | Oxygen scavenging compositions comprising polymers derived from tetrahydrofurfuryl monomers |
US6887270B2 (en) | 2002-02-08 | 2005-05-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US7022258B2 (en) * | 2002-02-14 | 2006-04-04 | Chevron Phillips Chemical Company, Lp | Oxygen scavenging compositions comprising polymers derived from benzenedimethanol monomers |
JP2003253031A (en) | 2002-02-28 | 2003-09-10 | Toray Ind Inc | Biodegradable crosslinked resin foam |
US20030204239A1 (en) | 2002-04-26 | 2003-10-30 | Wenda Carlyle | Endovascular stent with a preservative coating |
DE60303705T2 (en) | 2002-05-14 | 2006-10-19 | Terumo K.K. | Coated stent for the release of active substances |
CN1215156C (en) * | 2002-07-12 | 2005-08-17 | 吕新 | Color-flame candle and method for making same |
US6962714B2 (en) | 2002-08-06 | 2005-11-08 | Ecolab, Inc. | Critical fluid antimicrobial compositions and their use and generation |
US20040063805A1 (en) | 2002-09-19 | 2004-04-01 | Pacetti Stephen D. | Coatings for implantable medical devices and methods for fabrication thereof |
US7087263B2 (en) | 2002-10-09 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Rare limiting barriers for implantable medical devices |
US7704518B2 (en) * | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
AU2003293082A1 (en) | 2002-11-27 | 2004-06-23 | Tufts University | Antioxidant-functionalized polymers |
US8088404B2 (en) | 2003-03-20 | 2012-01-03 | Medtronic Vasular, Inc. | Biocompatible controlled release coatings for medical devices and related methods |
US8801692B2 (en) | 2003-09-24 | 2014-08-12 | Medtronic Vascular, Inc. | Gradient coated stent and method of fabrication |
US7055237B2 (en) | 2003-09-29 | 2006-06-06 | Medtronic Vascular, Inc. | Method of forming a drug eluting stent |
US20050074406A1 (en) | 2003-10-03 | 2005-04-07 | Scimed Life Systems, Inc. | Ultrasound coating for enhancing visualization of medical device in ultrasound images |
US6984411B2 (en) | 2003-10-14 | 2006-01-10 | Boston Scientific Scimed, Inc. | Method for roll coating multiple stents |
US8394446B2 (en) | 2005-07-25 | 2013-03-12 | Abbott Cardiovascular Systems Inc. | Methods of providing antioxidants to implantable medical devices |
US7785647B2 (en) * | 2005-07-25 | 2010-08-31 | Advanced Cardiovascular Systems, Inc. | Methods of providing antioxidants to a drug containing product |
US8309671B2 (en) | 2005-10-24 | 2012-11-13 | Lucite International, Inc. | Extrudable acrylic compositions |
US8128688B2 (en) | 2006-06-27 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Carbon coating on an implantable device |
US20090319031A1 (en) * | 2008-06-19 | 2009-12-24 | Yunbing Wang | Bioabsorbable Polymeric Stent With Improved Structural And Molecular Weight Integrity |
US8207240B2 (en) * | 2009-09-14 | 2012-06-26 | Abbott Cardiovascular Systems Inc | Method to minimize molecular weight drop of poly(L-lactide) stent during processing |
-
2005
- 2005-07-25 US US11/189,216 patent/US7785647B2/en not_active Expired - Fee Related
-
2006
- 2006-07-11 WO PCT/US2006/027050 patent/WO2007018931A2/en active Application Filing
- 2006-09-27 US US11/528,891 patent/US20070198080A1/en not_active Abandoned
-
2010
- 2010-08-05 US US12/851,420 patent/US9675737B2/en not_active Expired - Fee Related
- 2010-08-05 US US12/851,414 patent/US20100300917A1/en not_active Abandoned
Patent Citations (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2072303A (en) * | 1932-10-18 | 1937-03-02 | Chemische Forschungs Gmbh | Artificial threads, bands, tubes, and the like for surgical and other purposes |
US3429717A (en) * | 1965-05-24 | 1969-02-25 | Grace W R & Co | Flexible film wrapper |
US4733665B1 (en) * | 1985-11-07 | 1994-01-11 | Expandable Grafts Partnership | Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US5721131A (en) * | 1987-03-06 | 1998-02-24 | United States Of America As Represented By The Secretary Of The Navy | Surface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells |
US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US5100992A (en) * | 1989-05-04 | 1992-03-31 | Biomedical Polymers International, Ltd. | Polyurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same |
US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
US5298260A (en) * | 1990-05-01 | 1994-03-29 | Mediventures, Inc. | Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality |
US5607467A (en) * | 1990-09-14 | 1997-03-04 | Froix; Michael | Expandable polymeric stent with memory and delivery apparatus and method |
US6869443B2 (en) * | 1991-10-04 | 2005-03-22 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5858746A (en) * | 1992-04-20 | 1999-01-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US5380299A (en) * | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
US5857998A (en) * | 1994-06-30 | 1999-01-12 | Boston Scientific Corporation | Stent and therapeutic delivery system |
US5485496A (en) * | 1994-09-22 | 1996-01-16 | Cornell Research Foundation, Inc. | Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties |
US5879713A (en) * | 1994-10-12 | 1999-03-09 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US5869127A (en) * | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US6358556B1 (en) * | 1995-04-19 | 2002-03-19 | Boston Scientific Corporation | Drug release stent coating |
US6010530A (en) * | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
US20030036794A1 (en) * | 1995-06-07 | 2003-02-20 | Cook Incorporated | Coated implantable medical device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US20030028243A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US5865814A (en) * | 1995-06-07 | 1999-02-02 | Medtronic, Inc. | Blood contacting medical device and method |
US20030028244A1 (en) * | 1995-06-07 | 2003-02-06 | Cook Incorporated | Coated implantable medical device |
US5873904A (en) * | 1995-06-07 | 1999-02-23 | Cook Incorporated | Silver implantable medical device |
US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
US5723219A (en) * | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US6033582A (en) * | 1996-01-22 | 2000-03-07 | Etex Corporation | Surface modification of medical implants |
US5610241A (en) * | 1996-05-07 | 1997-03-11 | Cornell Research Foundation, Inc. | Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers |
US5876433A (en) * | 1996-05-29 | 1999-03-02 | Ethicon, Inc. | Stent and method of varying amounts of heparin coated thereon to control treatment |
US6172167B1 (en) * | 1996-06-28 | 2001-01-09 | Universiteit Twente | Copoly(ester-amides) and copoly(ester-urethanes) |
US5711958A (en) * | 1996-07-11 | 1998-01-27 | Life Medical Sciences, Inc. | Methods for reducing or eliminating post-surgical adhesion formation |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US6042875A (en) * | 1997-04-30 | 2000-03-28 | Schneider (Usa) Inc. | Drug-releasing coatings for medical devices |
US6180632B1 (en) * | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6528526B1 (en) * | 1997-05-28 | 2003-03-04 | Aventis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6524347B1 (en) * | 1997-05-28 | 2003-02-25 | Avantis Pharmaceuticals Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6034204A (en) * | 1997-08-08 | 2000-03-07 | Basf Aktiengesellschaft | Condensation products of basic amino acids with copolymerizable compounds and a process for their production |
US20050038134A1 (en) * | 1997-08-18 | 2005-02-17 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
US6037022A (en) * | 1997-09-16 | 2000-03-14 | International Paper Company | Oxygen-scavenging filled polymer blend for food packaging applications |
US6015541A (en) * | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US6344035B1 (en) * | 1998-04-27 | 2002-02-05 | Surmodics, Inc. | Bioactive agent release coating |
US6335029B1 (en) * | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6011125A (en) * | 1998-09-25 | 2000-01-04 | General Electric Company | Amide modified polyesters |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6689099B2 (en) * | 1999-07-13 | 2004-02-10 | Advanced Cardiovascular Systems, Inc. | Local drug delivery injection catheter |
US6177523B1 (en) * | 1999-07-14 | 2001-01-23 | Cardiotech International, Inc. | Functionalized polyurethanes |
US20040029952A1 (en) * | 1999-09-03 | 2004-02-12 | Yung-Ming Chen | Ethylene vinyl alcohol composition and coating |
US6713119B2 (en) * | 1999-09-03 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Biocompatible coating for a prosthesis and a method of forming the same |
US6346110B2 (en) * | 1999-10-04 | 2002-02-12 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implantable device |
US6203551B1 (en) * | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6503954B1 (en) * | 2000-03-31 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing actinomycin D and a method of forming the same |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US20020007213A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007215A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020005206A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20020007214A1 (en) * | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6673385B1 (en) * | 2000-05-31 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Methods for polymeric coatings stents |
US20040018296A1 (en) * | 2000-05-31 | 2004-01-29 | Daniel Castro | Method for depositing a coating onto a surface of a prosthesis |
US6689350B2 (en) * | 2000-07-27 | 2004-02-10 | Rutgers, The State University Of New Jersey | Therapeutic polyesters and polyamides |
US20040047978A1 (en) * | 2000-08-04 | 2004-03-11 | Hossainy Syed F.A. | Composition for coating an implantable prosthesis |
US6503538B1 (en) * | 2000-08-30 | 2003-01-07 | Cornell Research Foundation, Inc. | Elastomeric functional biodegradable copolyester amides and copolyester urethanes |
US6506437B1 (en) * | 2000-10-17 | 2003-01-14 | Advanced Cardiovascular Systems, Inc. | Methods of coating an implantable device having depots formed in a surface thereof |
US6503556B2 (en) * | 2000-12-28 | 2003-01-07 | Advanced Cardiovascular Systems, Inc. | Methods of forming a coating for a prosthesis |
US20040047980A1 (en) * | 2000-12-28 | 2004-03-11 | Pacetti Stephen D. | Method of forming a diffusion barrier layer for implantable devices |
US20030032767A1 (en) * | 2001-02-05 | 2003-02-13 | Yasuhiro Tada | High-strength polyester-amide fiber and process for producing the same |
US20030004141A1 (en) * | 2001-03-08 | 2003-01-02 | Brown David L. | Medical devices, compositions and methods for treating vulnerable plaque |
US6712845B2 (en) * | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US20030039689A1 (en) * | 2001-04-26 | 2003-02-27 | Jianbing Chen | Polymer-based, sustained release drug delivery system |
US20050004663A1 (en) * | 2001-05-07 | 2005-01-06 | Llanos Gerard H. | Heparin barrier coating for controlled drug release |
US20040052858A1 (en) * | 2001-05-09 | 2004-03-18 | Wu Steven Z. | Microparticle coated medical device |
US20040052859A1 (en) * | 2001-05-09 | 2004-03-18 | Wu Steven Z. | Microparticle coated medical device |
US6695920B1 (en) * | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US6673154B1 (en) * | 2001-06-28 | 2004-01-06 | Advanced Cardiovascular Systems, Inc. | Stent mounting device to coat a stent |
US6527863B1 (en) * | 2001-06-29 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Support device for a stent and a method of using the same to coat a stent |
US6706013B1 (en) * | 2001-06-29 | 2004-03-16 | Advanced Cardiovascular Systems, Inc. | Variable length drug delivery catheter |
US20030060877A1 (en) * | 2001-09-25 | 2003-03-27 | Robert Falotico | Coated medical devices for the treatment of vascular disease |
US20030059520A1 (en) * | 2001-09-27 | 2003-03-27 | Yung-Ming Chen | Apparatus for regulating temperature of a composition and a method of coating implantable devices |
US6709514B1 (en) * | 2001-12-28 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Rotary coating apparatus for coating implantable medical devices |
US6861088B2 (en) * | 2002-03-28 | 2005-03-01 | Boston Scientific Scimed, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US6865810B2 (en) * | 2002-06-27 | 2005-03-15 | Scimed Life Systems, Inc. | Methods of making medical devices |
US20040054104A1 (en) * | 2002-09-05 | 2004-03-18 | Pacetti Stephen D. | Coatings for drug delivery devices comprising modified poly(ethylene-co-vinyl alcohol) |
US20050049694A1 (en) * | 2003-08-07 | 2005-03-03 | Medtronic Ave. | Extrusion process for coating stents |
US20050038497A1 (en) * | 2003-08-11 | 2005-02-17 | Scimed Life Systems, Inc. | Deformation medical device without material deformation |
US20050037048A1 (en) * | 2003-08-11 | 2005-02-17 | Young-Ho Song | Medical devices containing antioxidant and therapeutic agent |
US20050037052A1 (en) * | 2003-08-13 | 2005-02-17 | Medtronic Vascular, Inc. | Stent coating with gradient porosity |
US20050043786A1 (en) * | 2003-08-18 | 2005-02-24 | Medtronic Ave, Inc. | Methods and apparatus for treatment of aneurysmal tissue |
US20050049693A1 (en) * | 2003-08-25 | 2005-03-03 | Medtronic Vascular Inc. | Medical devices and compositions for delivering biophosphonates to anatomical sites at risk for vascular disease |
US20050055078A1 (en) * | 2003-09-04 | 2005-03-10 | Medtronic Vascular, Inc. | Stent with outer slough coating |
US20050055044A1 (en) * | 2003-09-09 | 2005-03-10 | Scimed Life Systems, Inc. | Lubricious coatings for medical device |
US20050054774A1 (en) * | 2003-09-09 | 2005-03-10 | Scimed Life Systems, Inc. | Lubricious coating |
US20050060020A1 (en) * | 2003-09-17 | 2005-03-17 | Scimed Life Systems, Inc. | Covered stent with biologically active material |
US20050065593A1 (en) * | 2003-09-19 | 2005-03-24 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
US20050065545A1 (en) * | 2003-09-23 | 2005-03-24 | Scimed Life Systems, Inc. | External activation of vaso-occlusive implants |
US20050065501A1 (en) * | 2003-09-23 | 2005-03-24 | Scimed Life Systems, Inc. | Energy activated vaso-occlusive devices |
US20050064088A1 (en) * | 2003-09-24 | 2005-03-24 | Scimed Life Systems, Inc | Ultrasonic nozzle for coating a medical appliance and method for using an ultrasonic nozzle to coat a medical appliance |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100300917A1 (en) * | 2005-07-25 | 2010-12-02 | Ni Ding | Methods of providing antioxidants to a drug containing product |
US20100300903A1 (en) * | 2005-07-25 | 2010-12-02 | Ni Ding | Methods of providing antioxidants to a drug containing product |
US9675737B2 (en) | 2005-07-25 | 2017-06-13 | Abbott Cardiovascular Systems Inc. | Methods of providing antioxidants to a drug containing product |
US9655751B2 (en) | 2005-07-25 | 2017-05-23 | Abbott Cardiovascular Systems Inc. | Kits including implantable medical devices and antioxidants |
US8128688B2 (en) * | 2006-06-27 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Carbon coating on an implantable device |
US20080114096A1 (en) * | 2006-11-09 | 2008-05-15 | Hydromer, Inc. | Lubricious biopolymeric network compositions and methods of making same |
US9314552B2 (en) | 2006-11-20 | 2016-04-19 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US11534430B2 (en) | 2006-11-20 | 2022-12-27 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8932561B2 (en) | 2006-11-20 | 2015-01-13 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US11376404B2 (en) | 2006-11-20 | 2022-07-05 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US10994055B2 (en) | 2006-11-20 | 2021-05-04 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US10912931B2 (en) | 2006-11-20 | 2021-02-09 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8998847B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9005161B2 (en) | 2006-11-20 | 2015-04-14 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9023371B2 (en) | 2006-11-20 | 2015-05-05 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9033919B2 (en) | 2006-11-20 | 2015-05-19 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US10912932B2 (en) | 2006-11-20 | 2021-02-09 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9248220B2 (en) | 2006-11-20 | 2016-02-02 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US10881644B2 (en) | 2006-11-20 | 2021-01-05 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9289537B2 (en) | 2006-11-20 | 2016-03-22 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids |
US9289539B2 (en) | 2006-11-20 | 2016-03-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9314598B2 (en) | 2006-11-20 | 2016-04-19 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8403910B2 (en) | 2006-11-20 | 2013-03-26 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9402935B2 (en) | 2006-11-20 | 2016-08-02 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9283358B2 (en) | 2006-11-20 | 2016-03-15 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8404300B2 (en) | 2006-11-20 | 2013-03-26 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US10835719B2 (en) | 2006-11-20 | 2020-11-17 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8366662B2 (en) | 2006-11-20 | 2013-02-05 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8366660B2 (en) | 2006-11-20 | 2013-02-05 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9694111B2 (en) | 2006-11-20 | 2017-07-04 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9737691B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9757544B2 (en) | 2006-11-20 | 2017-09-12 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9757351B2 (en) | 2006-11-20 | 2017-09-12 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids and/or lipids |
US9764065B2 (en) | 2006-11-20 | 2017-09-19 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US10485959B2 (en) | 2006-11-20 | 2019-11-26 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US10485958B2 (en) | 2006-11-20 | 2019-11-26 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US9937159B2 (en) | 2006-11-20 | 2018-04-10 | Lutonix, Inc. | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9770576B2 (en) | 2008-08-29 | 2017-09-26 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US9180485B2 (en) | 2008-08-29 | 2015-11-10 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US20100280594A1 (en) * | 2009-05-01 | 2010-11-04 | Medi-Solve, Llc | Antithrombotic Neurovascular Device Containing a Glycoprotein IIB/IIIA Receptor Inhibitor for The Treatment of Brain Aneurysms and/or Acute Ischemic Stroke, and Methods Related Thereto |
US20110137407A1 (en) * | 2009-07-09 | 2011-06-09 | Thai Minh Nguyen | Bare metal stent with drug eluting reservoirs |
US20130192167A1 (en) * | 2010-09-17 | 2013-08-01 | Terumo Kabushiki Kaisha | Silicone rubber composition |
US9523001B2 (en) * | 2010-09-17 | 2016-12-20 | Terumo Kabushiki Kaisha | Silicone rubber composition |
RU2606436C2 (en) * | 2012-03-13 | 2017-01-10 | ТиссенКрупп Рассельштайн ГмбХ | Method for treating steel band or plate provided with metal coating with after-treatment agent, and steel band or plate provided with metal coating |
US9901663B2 (en) | 2013-05-06 | 2018-02-27 | Abbott Cardiovascular Systems Inc. | Hollow stent filled with a therapeutic agent formulation |
US10485901B2 (en) * | 2015-02-26 | 2019-11-26 | Battelle Memorial Institute | Implant with reactive oxygen species scavenging coating |
US11426495B2 (en) * | 2015-02-26 | 2022-08-30 | Battelle Memorial Institute | Implant with reactive oxygen species scavenging coating |
US10842917B2 (en) * | 2015-02-26 | 2020-11-24 | Battelle Memorial Institute | Implant with reactive oxygen species scavenging coating |
Also Published As
Publication number | Publication date |
---|---|
US20100300903A1 (en) | 2010-12-02 |
US7785647B2 (en) | 2010-08-31 |
US20100300917A1 (en) | 2010-12-02 |
US20070020380A1 (en) | 2007-01-25 |
US9675737B2 (en) | 2017-06-13 |
WO2007018931A2 (en) | 2007-02-15 |
WO2007018931A3 (en) | 2007-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070198080A1 (en) | Coatings including an antioxidant | |
US9421223B2 (en) | Nitric oxide generating medical devices | |
US8778376B2 (en) | Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating | |
US7637941B1 (en) | Endothelial cell binding coatings for rapid encapsulation of bioerodable stents | |
US7601383B2 (en) | Coating construct containing poly (vinyl alcohol) | |
US8703167B2 (en) | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug | |
US9067002B2 (en) | Tailored aliphatic polyesters for stent coatings | |
US20070005130A1 (en) | Biodegradable polymer for coating | |
US20120003291A1 (en) | Nanobead releasing medical devices | |
US8703293B2 (en) | Coating compositions and coatings for medical devices containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer | |
US20110144741A1 (en) | Coating Construct With Enhanced Interfacial Compatibility | |
US20160158420A1 (en) | Coatings formed from stimulus-sensitive material | |
US20080175882A1 (en) | Polymers of aliphatic thioester |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ABBOTT CARDIOVASCULAR SYSTEMS INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DING, NI;COLEMAN, LESLIE;REEL/FRAME:019221/0861;SIGNING DATES FROM 20070418 TO 20070423 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |